Carol Whelan

16.3k total citations · 2 hit papers
129 papers, 5.8k citations indexed

About

Carol Whelan is a scholar working on Molecular Biology, Nephrology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Carol Whelan has authored 129 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Molecular Biology, 58 papers in Nephrology and 23 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Carol Whelan's work include Amyloidosis: Diagnosis, Treatment, Outcomes (120 papers), Parathyroid Disorders and Treatments (54 papers) and Neuroendocrine Tumor Research Advances (14 papers). Carol Whelan is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (120 papers), Parathyroid Disorders and Treatments (54 papers) and Neuroendocrine Tumor Research Advances (14 papers). Carol Whelan collaborates with scholars based in United Kingdom, United States and Italy. Carol Whelan's co-authors include Philip N. Hawkins, Julian D. Gillmore, Ashutosh Wechalekar, Helen J. Lachmann, Marianna Fontana, James Moon, Janet A. Gilbertson, Dorota Rowczenio, Sanjay M Banypersad and Jennifer H. Pinney and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

Carol Whelan

119 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis

2013 475 citations Marianna Fontana, Carol Whelan et al. profile →
A new staging system for cardiac transthyretin amyloidosis

2017 453 citations Julian D. Gillmore, Marianna Fontana et al. profile →

Peers

Countries citing papers authored by Carol Whelan

Since Specialization

Citations

This map shows the geographic impact of Carol Whelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Whelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Whelan more than expected).

Fields of papers citing papers by Carol Whelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Whelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Whelan. The network helps show where Carol Whelan may publish in the future.

Co-authorship network of co-authors of Carol Whelan

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Whelan. A scholar is included among the top collaborators of Carol Whelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Whelan. Carol Whelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis 2025 ·British Journal of Haematology ·Jahanzaib Khwaja, Sriram Ravichandran, Oliver C. Cohen, Darren Foard, (unknown), Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Shameem Mahmood, Ashutosh Wechalekar	1
2	Association Between Deviations From Cerebral Autoregulation–Derived Optimal Blood Pressure and Outcome After Pediatric Cardiac Arrest 2025 ·Neurology ·Matthew P. Kirschen, Andrea L.C. Schneider, (unknown), Jesse Y. Hsu, Ryan Burnett, Rebecca L. Douglas, (unknown), Kathryn Graham, (unknown), Carol Whelan, Tiffany S. Ko, Ryan W. Morgan, Vinay Nadkarni, Ramon Diaz‐Arrastia, (unknown), Alexis Topjian	0
3	Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System 2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver C. Cohen, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Amy A. Kirkwood, Ashutosh Wechalekar	0
4	Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis 2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, (unknown), Ashutosh Wechalekar	0
5	5 Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy – a study of natural history and treatment repsonse 2024 ·Abstracts ·Rishi Patel, Ana Martinez–Naharro, Yousuf Razvi, Adam Ioannou, Aldostefano Porcari, Liza Chacko, James Brown, Daniel Knight, Tushar Kotecha, Charlotte Manisty, James Moon, Helen J. Lachmann, Ashutosh Wechalekar, Carol Whelan, Lucia Venneri, Peter Kellman, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana	1
6	OP0323 CAUSES OF AA AMYLOIDOSIS: ANALYSIS OF 952 PATIENTS SEEN AT A REFERENCE CENTRE OVER 34 YEARS 2024 ·Annals of the Rheumatic Diseases ·Helen J. Lachmann, Oliver Cohen, Marianna Fontana, Janet A. Gilbertson, Julian D. Gillmore, Philip N. Hawkins, S. Mahmood, (unknown), (unknown), Sriram Ravichandran, Dorota Rowczenio, Ashutosh Wechalekar, Carol Whelan	1
7	Effect of Beta-Blockade on Mortality in Patients with Cardiac Amyloidosis: A Systematic Review and Meta-Analysis 2024 ·ESC Heart Failure ·Chun Shing Kwok, (unknown), Jennifer H. Pinney, John Townend, Carol Whelan, Marianna Fontana, Julian D. Gillmore, Richard P. Steeds, William E. Moody	5
8	Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients 2023 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver Cohen, Darren Foard, (unknown), Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh Wechalekar	5
9	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy 2021 ·Heart ·Steven Law, Aviva Petrie, Liza Chacko, Oliver Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez–Naharro, Helen J. Lachmann, Carol Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore	20
10	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis 2021 ·European Heart Journal - Cardiovascular Imaging ·Candida Cristina Quarta, (unknown), David F. Hutt, (unknown), Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Carol Whelan, Marianna Fontana, Ana Martinez–Naharro, Liza Chacko, Helen J. Lachmann, Julian D. Gillmore, Claudio Rapezzi, Philip N. Hawkins, Ashutosh Wechalekar	42
11	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis 2020 ·British Journal of Haematology ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	28
12	Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers 2019 ·British Journal of Haematology ·Tamer Rezk, Helen J. Lachmann, Marianna Fontana, (unknown), Sajitha Sachchithanantham, Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Philip N. Hawkins, Julian D. Gillmore	15
13	Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis 2018 ·British Journal of Haematology ·Tamer Rezk, Andrew Davenport, (unknown), Helen J. Lachmann, Marianna Fontana, Ana Martinez–Naharro, Sajitha Sachchithanantham, (unknown), Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Philip N. Hawkins, Julian D. Gillmore	4
14	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis 2018 ·British Journal of Haematology ·Faye Sharpley, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, (unknown), Carol Whelan, Philip N. Hawkins, Ashutosh Wechalekar	12
15	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis 2017 ·British Journal of Haematology ·Tamer Rezk, Carol Whelan, Helen J. Lachmann, Marianna Fontana, Sajitha Sachchithanantham, Shameem Mahmood, Fakhar Z. Khan, Raj Khiani, Joseph Tomson, Taryn Youngstein, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	17
16	Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study 2017 ·Blood ·Richa Manwani, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Carol Whelan, Candida Cristina Quarta, Thirusha Lane, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	1
17	Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance 2016 ·Circulation ·Ana Martinez–Naharro, Amna Abdel‐Gadir, Thomas A. Treibel, Giulia Zumbo, Daniel Knight, Stefania Rosmini, Thirusha Lane, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Helen J. Lachmann, Ashutosh Wechalekar, Peter Kellman, Julian D. Gillmore, James Moon, Philip N. Hawkins, Marianna Fontana	2
18	Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy 2015 ·Neuromuscular Disorders ·(unknown), Ana L. Pelayo‐Negro, Zane Jaunmuktane, R. Scalco, David F. Hutt, (unknown), (unknown), Sebastian Brandner, Janice L. Holton, J. Blake, Carol Whelan, Ashutosh Wechalekar, Julian D. Gillmore, Philip N. Hawkins, Mary M. Reilly	19
19	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study 2015 ·The Lancet Haematology ·Shameem Mahmood, Frank Bridoux, Christopher P. Venner, Sajitha Sachchithanantham, Janet A. Gilbertson, Dorota Rowczenio, Thomas Wagner, Rabya Sayed, Ketna Patel, Marianna Fontana, Carol Whelan, Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore, Ashutosh Wechalekar	95
20	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival 2012 ·Blood ·Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon Gibbs, Jennifer H. Pinney, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	197

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact